Efficacy of ActiveMatrix on Spinal SSI Rate

Status Not yet recruiting

Clinical Trial Summary

This clinical trial seeks to provide high level of evidence on the efficacy of ActiveMatrix primarily on spinal surgical site infection rate.

Clinical Trial Description

Postoperative spinal surgical site infections (SSI) have a significant effect on patient morbidity and mortality.1 Spinal SSI as well as other complications including pseudoarthrosis occur at a higher rate in patients with comorbidities including obesity, smoking history, diabetes, steroid use, older age, and higher modified frailty index.2 Patients of Veterans Affairs (VA) medical centers have higher number of comorbidities than non-VA patients, and are therefore at higher risk for postoperative spinal SSI and complications.3,4 Spinal SSI has been reported to be anywhere from <1% in decompressions to >10% after instrumented fusion.5 Anecdotal evidence has suggested SSI to be as high as 20% among our population. As spine surgeons for the largest VA in the country, our team sought a product that could reduce the rate of spinal SSI, and ideally result in improved patient outcomes, in our at-risk patient population. Skye Biologics offers placental tissue-based matrices in the form of both flowable and solid mediums. The flowable matrix has been shown in-vitro to contain significant amounts of collagen and growth factors, as well as molecules known to modulate immune response. The results of this have been in-vitro inhibition of methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus saprophyticus proliferation, increase in migration of adipose-derived stem cells (ASCs), adherence to the ASCs in cultures.6 In translation of these results clinical application has been well received, with various subspecialties including ENT and orthopedics using the products. Based on both the positive in vitro and in vivo results, out team began using the flowable product with good initial subjective results, including improved wound healing and excellent patient satisfaction. The true clinical efficacy remains to be assessed, however. Our team sought to provide level 1 evidence on this product in thoracolumbosacaral posterior spinal decompression and/or fusion in our at-risk population via a single-blinded randomized control trial at high-volume institution (s). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05297513
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Not yet recruiting
Phase	Phase 4
Start date	July 2022
Completion date	July 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04096885` - The Inselspital Surgical Cohort Study
Terminated	`NCT03820648` - Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy	N/A
Completed	`NCT04067843` - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study	N/A
Terminated	`NCT04042077` - Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections	Phase 3
Completed	`NCT05841576` - Anaesthetic Management Guided by COMET Measurements	N/A
Withdrawn	`NCT05338281` - NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT	N/A
Recruiting	`NCT03042091` - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery	Early Phase 1
Completed	`NCT01697748` - Prospective Study on Cesarean Wound Outcomes	N/A
Terminated	`NCT01789697` - Text Message Study	N/A
Recruiting	`NCT05966961` - Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
Recruiting	`NCT05077592` - Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections	Phase 4
Recruiting	`NCT05763602` - PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)	Phase 4
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Recruiting	`NCT03221023` - Intrawound Vancomycin Prophylaxis for Neural Stimulator	Phase 2/Phase 3
Completed	`NCT03257202` - Topical Treatment and Prevalence of P. Acnes	Phase 2
Completed	`NCT06154720` - Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
Not yet recruiting	`NCT06465901` - A Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI	N/A
Not yet recruiting	`NCT04820075` - Efficacy of an Intervention to Improve the Preoperative Shower in Scheduled Surgery	N/A
Recruiting	`NCT03561376` - Zinc Oxide Versus Petrolatum Following Skin Surgery	Early Phase 1
Not yet recruiting	`NCT04496180` - Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.